n n n ‘. concat(e. i18n. t(“search. voice. recognition_retry”),’n
TOKYO, December 06, 2023–(BUSINESS WIRE)–Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Minoru Tanaka)(TOKYO:4118) has acquired all shares of Japan Medical Device Technology Co., Ltd. (Headquarters: Kamimashiki-gun, Kumamoto; President: Shuzo Yamashita) (hereinafter JMDT), a developer and manufacturer of medical devices, on November 30, 2023, and made it a wholly owned subsidiary.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231206372197/en/
Stent before (Photo: Business Wire)
Kaneka manufactures and sells endovascular catheters, which are devices used in the treatment of central, peripheral, and cerebrovascular diseases. In particular, stenting*1 for the treatment of central coronary heart diseases such as atherosclerosis has a market value of 30 billion yen in Japan, and Kaneka intends to expand its business in this area. JMDT has state-of-the-art technological functions in the study and progression of coronary products. It is one of the leaders in the progression of bioresorbable stents*2.
Coronary artery treatment usually involves placing a tubular cord mesh stent into the lesion to widen the lumen and repair blood flow. However, because the stent remains in the blood vessel, another stent cannot be placed in the same place at the time. of a recurrence of restenosis. JMDT’s bioabsorbable stent is made of a biodegradable magnesium alloy, which causes vessel obstruction potentially caused by the stent remaining in the vessel. In addition, 95% of the stent is reabsorbed and absorbed through the framework 1 1/2 years after implantation, ensuring that it does not interfere with the treatment of restenosis.
*1. A stent is a small, elastic tubular cord mesh made of metals such as a cobalt-chromium alloy or a nickel-titanium alloy. It is a medical device that widens the tubular portions of the human structure (blood vessels, trachea, esophagus, duodenum, colon, bile ducts, etc. ) from within the lumen. They are fixed in a catheter and dilated into the arteries to treat narrowed or blocked coronary arteries or peripheral arteries in the lower extremities. Implantation of a stent restores blood flow to the remedy site.
*2. JMDT’s bioabsorbable stent is made of a high-magnesium alloy and has a low risk of thrombosis due to a thin (100 μm) but fully expandable body. Its surface is covered with a layer that controls the degradation of the magnesium alloy and the elution of the drug (Sirolimus). In addition, it is lately the only bioresorbent stent in Japan that has gone to the FIH (First In Human) trial for use in humans for the first time.
[Japan Medical Device Technology Co. , Ltd. de]
Representative:
Shuzo Yamashita
Share capital:
10 million yen
Headquarters:
Kumamoto. D Technology Incubation Center Building, 2020-3 Tabaru,
Mashiki-machi, Kamimashiki-gun, Kumamoto, 861-2202
Base:
October 2014
Enterprise:
Research and progression of coronary stents and traditional progression of medical devices.
Bioresorbent Stent Introduction Video (by JMDT): https://www. youtube. com/watch?v=CrFBhuQCIf4
See the edition on businesswire. com: https://www. businesswire. com/news/home/20231206372197/en/
Contacts
KANEKA CORPORATIONDutcha HaradaInfo_Pro@kaneka. co. jp Public Relations and Investor Department